Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK112 plus etoposide and carboplatin as first-line treatment for extensive-stage small cell lung cancer
ChiCTR2400087910Phase 2Not yet recruiting
- Sponsor
- Jilin Provincial Cancer Hospital
- Start
- Aug 2024
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ivonescimab, etoposide and carboplatin in small cell lung cancer (SCLC), sponsored by Jilin Provincial Cancer Hospital. Primary endpoint: Objective response rate. Planned start Aug 2024; status: not yet recruiting.
02
Drugs
ivonescimabetoposidecarboplatin
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ChiCTR2400087910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400087910.